Literature DB >> 11241277

Increased expression of type 2 cytokines in chronic proliferative dermatitis (cpdm) mutant mice and resolution of inflammation following treatment with IL-12.

H HogenEsch1, S E Torregrosa, D Boggess, B A Sundberg, J Carroll, J P Sundberg.   

Abstract

Chronic proliferative dermatitis (cpdm) is a spontaneous mutation that results in eosinophilic inflammation in multiple tissues, including the skin. To determine the mechanisms underlying the eosinophilic inflammation, the expression of cytokines in the skin was determined. There was increased expression of IL-4, IL-5, IL-13, and granulocyte-macrophage colony-stimulating factor in the skin of cpdm/cpdm mice, and no change in IL-10 and TNF expression. Supernatants of cultured spleen cells of cpdm/cpdm mice contained an increased amount of IL-5 and IL-13, and a decreased amount of IFN-gamma. The ability of the cpdm/cpdm mice to mount a delayed-type hypersensitivity response was greatly reduced. These data are consistent with impaired type 1 and excessive type 2 cytokine production in cpdm/cpdm mice. The significance of this imbalanced cytokine production was evident in the efficacy of systemic treatment of cpdm/cpdm mice with IL-12. Mutant mice treated for 3 weeks with IL-12 had minimal changes in the skin as opposed to the severe dermatitis in mice treated with the vehicle. Treatment with IL-11, which opposes the effect of IL-12, had no effect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241277     DOI: 10.1002/1521-4141(200103)31:3<734::aid-immu734>3.0.co;2-9

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  24 in total

1.  SHARPIN regulates mitochondria-dependent apoptosis in keratinocytes.

Authors:  Yanhua Liang; John P Sundberg
Journal:  J Dermatol Sci       Date:  2011-05-07       Impact factor: 4.563

2.  Differential Involvement of the Npl4 Zinc Finger Domains of SHARPIN and HOIL-1L in Linear Ubiquitin Chain Assembly Complex-Mediated Cell Death Protection.

Authors:  Satoshi Shimizu; Hiroaki Fujita; Yoshiteru Sasaki; Tatsuaki Tsuruyama; Kazuhiko Fukuda; Kazuhiro Iwai
Journal:  Mol Cell Biol       Date:  2016-05-02       Impact factor: 4.272

3.  Skin Diseases in Laboratory Mice: Approaches to Drug Target Identification and Efficacy Screening.

Authors:  John P Sundberg; Kathleen A Silva; Lloyd E King; C Herbert Pratt
Journal:  Methods Mol Biol       Date:  2016

4.  Systems analysis identifies an essential role for SHANK-associated RH domain-interacting protein (SHARPIN) in macrophage Toll-like receptor 2 (TLR2) responses.

Authors:  Daniel E Zak; Frank Schmitz; Elizabeth S Gold; Alan H Diercks; Jacques J Peschon; Joe S Valvo; Antti Niemistö; Irina Podolsky; Shannon G Fallen; Rosa Suen; Tetyana Stolyar; Carrie D Johnson; Kathleen A Kennedy; M Kristina Hamilton; Owen M Siggs; Bruce Beutler; Alan Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

5.  Angiogenesis in the skin of SHARPIN-deficient mice with chronic proliferative dermatitis.

Authors:  Harm HogenEsch; Mario Sola; Timothy M Stearns; Kathleen A Silva; Victoria E Kennedy; John P Sundberg
Journal:  Exp Mol Pathol       Date:  2016-10-26       Impact factor: 3.362

6.  Inhibition of NF-κB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice.

Authors:  Yanhua Liang; Rosemarie E Seymour; John P Sundberg
Journal:  J Invest Dermatol       Date:  2010-09-02       Impact factor: 8.551

7.  Linear ubiquitination prevents inflammation and regulates immune signalling.

Authors:  Björn Gerlach; Stefanie M Cordier; Anna C Schmukle; Christoph H Emmerich; Eva Rieser; Tobias L Haas; Andrew I Webb; James A Rickard; Holly Anderton; Wendy W-L Wong; Ueli Nachbur; Lahiru Gangoda; Uwe Warnken; Anthony W Purcell; John Silke; Henning Walczak
Journal:  Nature       Date:  2011-03-31       Impact factor: 49.962

8.  The pathogenesis of chronic eosinophilic esophagitis in SHARPIN-deficient mice.

Authors:  Syu-Jhe Chien; Kathleen A Silva; Victoria E Kennedy; Harm HogenEsch; John P Sundberg
Journal:  Exp Mol Pathol       Date:  2015-08-29       Impact factor: 3.362

9.  Anti-IL5 decreases the number of eosinophils but not the severity of dermatitis in Sharpin-deficient mice.

Authors:  Matthew L Renninger; Rosemarie E Seymour; Laurence O Whiteley; John P Sundberg; Harm Hogenesch
Journal:  Exp Dermatol       Date:  2009-07-23       Impact factor: 3.960

10.  SHARPIN controls the development of regulatory T cells.

Authors:  Vanessa Redecke; Vandana Chaturvedi; Jeeba Kuriakose; Hans Häcker
Journal:  Immunology       Date:  2016-04-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.